07:00 , Jun 17, 2002 |  BC Week In Review  |  Clinical News

T902611: TLRK said it discontinued development of T611 in order to focus its clinical efforts. The company said studies of T611, which was in Phase II testing f

Tularik Inc. (TLRK), South San Francisco, Calif.   Product: T902611 (T611)   Business: Infectious diseases   Therapeutic category: Viral replication   Target: CMV primase   Description: Selective inhibitor of a cytomegalovirus (CMV) enzyme required for replication   Indication: Prevent cytomegalovirus...
07:00 , Apr 22, 2002 |  BC Week In Review  |  Clinical News

T902611: TLRK will begin 2 Phase II trials in the U.S. and Europe this quarter. Each trial will include 60-70 patients.

Tularik Inc. (TLRK), South San Francisco, Calif.   Product: T902611 (T611)   Business: Infectious diseases   Therapeutic category: Viral replication   Target: CMV primase   Description: Selective inhibitor of a cytomegalovirus (CMV) enzyme required for replication   Indication: Prevent cytomegalovirus...